NZ630912A - Nanoparticle compositions of albumin and paclitaxel - Google Patents

Nanoparticle compositions of albumin and paclitaxel

Info

Publication number
NZ630912A
NZ630912A NZ630912A NZ63091213A NZ630912A NZ 630912 A NZ630912 A NZ 630912A NZ 630912 A NZ630912 A NZ 630912A NZ 63091213 A NZ63091213 A NZ 63091213A NZ 630912 A NZ630912 A NZ 630912A
Authority
NZ
New Zealand
Prior art keywords
albumin
paclitaxel
nanoparticle compositions
compositions
nanoparticles
Prior art date
Application number
NZ630912A
Other languages
English (en)
Inventor
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ630912A publication Critical patent/NZ630912A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ630912A 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel NZ630912A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
NZ630912A true NZ630912A (en) 2017-05-26

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630912A NZ630912A (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Country Status (19)

Country Link
US (2) US20140186447A1 (cg-RX-API-DMAC7.html)
EP (1) EP2938340A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016504362A (cg-RX-API-DMAC7.html)
KR (1) KR20150100903A (cg-RX-API-DMAC7.html)
CN (1) CN105007912A (cg-RX-API-DMAC7.html)
AU (1) AU2013370955B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015015319A2 (cg-RX-API-DMAC7.html)
CA (1) CA2896288A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150386A (cg-RX-API-DMAC7.html)
HK (1) HK1216611A1 (cg-RX-API-DMAC7.html)
IL (1) IL239593A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015008361A (cg-RX-API-DMAC7.html)
NI (1) NI201500090A (cg-RX-API-DMAC7.html)
NZ (1) NZ630912A (cg-RX-API-DMAC7.html)
PH (1) PH12015501486B1 (cg-RX-API-DMAC7.html)
RU (1) RU2663687C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201505111TA (cg-RX-API-DMAC7.html)
WO (1) WO2014105644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504762B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
MX388073B (es) 2014-11-25 2025-03-19 Nanobiotix Composición farmacéutica, preparación y usos de la misma.
TW201628644A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
DK3229776T3 (da) 2014-11-25 2023-07-31 Curadigm Sas Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf
HUE056175T2 (hu) 2014-11-25 2022-01-28 Curadigm Sas Gyógyászati készítmények, elõállításuk és alkalmazásaik
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
WO2021086946A1 (en) * 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
EP4375659B1 (en) * 2022-11-28 2025-03-26 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
SG10201609290PA (en) * 2009-08-25 2016-12-29 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
BR112012024349A2 (pt) * 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
MX2015008361A (es) 2016-03-11
RU2663687C2 (ru) 2018-08-08
JP2018087241A (ja) 2018-06-07
JP2016504362A (ja) 2016-02-12
ZA201504762B (en) 2016-10-26
AU2013370955B2 (en) 2018-12-06
US20140186447A1 (en) 2014-07-03
CA2896288A1 (en) 2014-07-03
IL239593A0 (en) 2015-08-31
RU2015131141A (ru) 2017-02-03
SG11201505111TA (en) 2015-07-30
CN105007912A (zh) 2015-10-28
PH12015501486B1 (en) 2020-12-16
CR20150386A (es) 2015-10-07
EP2938340A1 (en) 2015-11-04
WO2014105644A1 (en) 2014-07-03
US20190192477A1 (en) 2019-06-27
EP2938340A4 (en) 2016-08-03
KR20150100903A (ko) 2015-09-02
NI201500090A (es) 2015-12-22
PH12015501486A1 (en) 2015-09-21
AU2013370955A1 (en) 2015-07-16
HK1216611A1 (zh) 2016-11-25
BR112015015319A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
NZ630912A (en) Nanoparticle compositions of albumin and paclitaxel
IL258055B (en) Preparations and methods for administering a modified dendrimer nanoparticle vaccine
PH12016502066A1 (en) Methods of treating bladder cancer
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
AU346291S (en) Medical dressing
EP2841486A4 (en) POLYMERNANOPARTICLES AND METHOD FOR THE MANUFACTURE THEREOF
EP3137116A4 (en) Dendrimer compositions and their use in treatment of diseases of the eye
EP3129062A4 (en) Targeted polymerized nanoparticles for cancer treatment
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL238662A (en) Bandostatin derivatives, containing them and used to treat cancer
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
IL243171A0 (en) Polymeric nanoparticles of docetaxel for use in cancer treatment
EP3220895A4 (en) The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2012040331A3 (en) Multistage nanoparticles
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
SG2013095823A (en) Novel acryl monomer, polymer and resist composition comprising the same
IN2012DE00138A (cg-RX-API-DMAC7.html)
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
JO3630B1 (ar) توليفة أليسيرتيب وباكليتاكسيل لعلاج السرطان
AU344226S (en) Wheel
AU2014903031A0 (en) Nanoparticle Composition and Uses in Photodynamic Therapy
EP3015860A4 (en) Super-complex formed by cross-binding between complexes of repeating chain and monomer, and use thereof
EP2848587A4 (en) METHOD FOR POLYMERIZING ON NANOPARTICLES AND POLYMER THUS OBTAINED

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2018 BY AJ PARK

Effective date: 20171129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2021 BY CPA GLOBAL

Effective date: 20201105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2022 BY CPA GLOBAL

Effective date: 20211104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2023 BY CPA GLOBAL

Effective date: 20221108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2024 BY CPA GLOBAL

Effective date: 20231102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251106